| This week's sponsor is Premier Research. | |  | Overcoming Risk in Oncology Drug Development
Oncology drug development is fraught with obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. It's what we do. Best. |
Today's Rundown Featured Story | | | Friday, May 3, 2019 Acacia Pharma has suffered its second FDA rejection in seven months. The British drug developer moved quickly to bounce back from the complete response letter it received in October, only to be hit with a second rejection after its contract manufacturer failed to resolve the problems. |
|
|
Top Stories Friday, May 3, 2019 Eisai has put Michael Irizarry in charge of its Alzheimer’s disease clinical development programs. The ex-Eli Lilly and GlaxoSmithKline researcher is taking on the role in the wake of aducanumab’s failure. Friday, May 3, 2019 What do you do when you’re studying age-related diseases but can’t hang about waiting for tissue models to reach a ripe old age? You blast them into outer space, naturally. The NIH and International Space Station U.S. National Laboratory sent up a second batch of tissues-on-a-chip, including chips modeling the kidney, lung and the blood-brain barrier. Monday, April 29, 2019 The prominence of emerging biotech looms large on the drug development landscape. CROs continue to adjust their core competencies and cultural mindset to tailor services for specific biotech needs. Friday, May 3, 2019 Interim data from a phase 1 study of Celgene and Bluebird Bio's CAR-T treatment for multiple myeloma, bb2121, showed median progression-free survival of about a year. But a high relapse rate could compound concerns about the durability of the treatment, which is a key asset in Bristol-Myers Squibb's $74 billion buyout of Celgene. Friday, May 3, 2019 Precision medicine software developer Syapse has launched a collaboration with its one-time Big Pharma benefactor Amgen, with the goal of mining real-world evidence for insights into cancer drug development. Thursday, May 2, 2019 In this week's EuroBiotech Report, AstraZeneca inks oncolytic virus deal, Bicycle files for IPO and Alentis raises series A round. Friday, May 3, 2019 AstraZeneca warns of slower China growth after losing out to local generic in a procurement plan. BeiGene chief becomes the second-highest-paid biopharma CEO in 2018. China's Kangmei Pharma faces potential delisting after a $4.4 billion accounting "error." And more. Friday, May 3, 2019 CMO Iannone walks out on troubled Immunomedics; uBiome CEOs take administrative leave following FBI raid; and longtime Gilead CFO announces plans to retire, leaving the new CEO with a hole to fill. Those moves plus more hirings, firings and retirings throughout the industry. | This week's sponsor is ExL Events. | |  | |
Resources Sponsored by: Patheon, part of Thermo Fisher Scientific Choosing the Best Sterile Dosage Form for Your Phase I Clinical Supply Needs. Sponsored by: Patheon, part of Thermo Fisher Scientific Designed with speed & flexibility,Quick to Clinic™ for Oral Solid Dose helps deliver products to Phase I Clinic in as little as 14 weeks. Sponsored by: JPEO-CBRND – Medical Countermeasure Systems MCS is currently seeking broad-based industry/academia collaboration on research and prototype work in technical areas related to developing medical countermeasures for the Joint Warfighter. Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Elemental Machines Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”. Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
